Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,866 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 45,838 · Balance 343,866 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 384,058 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 384,058 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 314,058 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 70,000 · Balance 314,058 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 404,608 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 22, 2021 Filed Mar 25, 2021 01:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.64 | $16,400.00 |
DisclosureSEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:42 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 403 | $39.57 | $15,946.71 |
DisclosureSEC source: 0001437749-21-004766 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,997 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,728 | $40.76 | $192,713.28 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,400 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,741 | $40.67 | $192,816.47 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,128 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,640 | $41.55 | $192,792.00 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,869 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 4,891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,891 Underlying: Common Stock · 4,891 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 33,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 4,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003517 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,313 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,483 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-21-002263 · rdgdoc.xml · derivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,483 shares Expires 2021-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The employee stock option vested in four equal annual installments commencing on 02/11/2012. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,483 | $40.02 | $739,689.66 |
DisclosureSEC source: 0001437749-21-002263 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,422 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $40.62, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,483 | $1.12 | $20,719.44 |
DisclosureSEC source: 0001437749-21-002263 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,484 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,483 Underlying: Common Stock · 18,484 shares Expires 2021-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The employee stock option vested in four equal annual installments commencing on 02/11/2012. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,484 | $40.23 | $743,611.32 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,422 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.83 inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,484 | $1.12 | $20,720.56 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 18,484 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,967 Underlying: Common Stock · 18,484 shares Expires 2021-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The employee stock option vested in four equal annual installments commencing on 02/11/2012. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 18,484 | $38.71 | $715,515.64 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,422 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $39.70, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 18,484 | $1.12 | $20,720.56 |
DisclosureSEC source: 0001437749-21-001915 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 380 | $35.49 | $13,486.20 |
DisclosureSEC source: 0001437749-20-024808 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,422 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,858 | $28.63 | $53,194.54 |
DisclosureSEC source: 0001437749-20-020641 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,802 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 23, 2020 Filed Sep 26, 2020 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,000 | $26.84 | $134,200.00 |
DisclosureSEC source: 0001437749-20-020293 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,660 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.51 to $27.23, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 26, 2020 Filed Aug 29, 2020 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 255 | $20.48 | $5,222.40 |
DisclosureSEC source: 0001437749-20-018961 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,660 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,000 | $19.68 | $98,400.00 |
DisclosureSEC source: 0001437749-20-017872 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,915 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. Read SEC document |
| August 11, 2020 Filed Aug 14, 2020 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $20.03 | $200,300.00 |
DisclosureSEC source: 0001437749-20-017872 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,915 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.57 to $21.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2020 Filed Jul 18, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $19.48 | $194,800.00 |
DisclosureSEC source: 0001437749-20-015367 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,915 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $19.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 242 | $16.87 | $4,082.54 |
DisclosureSEC source: 0001437749-20-012243 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,915 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-011067 · rdgdoc.xml · derivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,837 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $14.29 | $142,900.00 |
DisclosureSEC source: 0001437749-20-011067 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,157 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.04 to $14.96, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-20-011067 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,837 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $15.42 | $154,200.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,157 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.38 to $15.48, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,837 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.40 | $134,000.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,157 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 11, 2020 Filed May 14, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 13,718 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006399 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,718 Underlying: Common Stock · 13,718 shares Expires not disclosed F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 22,863 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006399 · rdgdoc.xml · derivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,863 Underlying: Common Stock · 22,863 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 22,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,157 F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,294 F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. Read SEC document |
| March 25, 2020 Filed Mar 28, 2020 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,144 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,706 F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. Read SEC document |
| March 24, 2020 Filed Mar 27, 2020 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $9.25 | $92,500.00 |
DisclosureSEC source: 0001437749-20-006243 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,562 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,024 | $15.02 | $15,380.48 |
DisclosureSEC source: 0001437749-20-004026 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,562 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,966 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · derivative · entry 9 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,966 shares Expires 2020-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $14.06 | $140,600.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 6 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,586 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.23, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 17,966 | $1.40 | $25,170.37 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 5 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · derivative · entry 8 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,966 Underlying: Common Stock · 10,000 shares Expires 2020-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $14.10 | $141,000.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,620 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.15, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.40 | $14,010.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · derivative · entry 7 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,966 Underlying: Common Stock · 10,000 shares Expires 2020-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $13.63 | $136,300.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,620 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $13.80, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.40 | $14,010.00 |
DisclosureSEC source: 0001437749-20-001830 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.